Evidence map›Paper›PMID 41811471›Full record

ReviewRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2026

Delafloxacin: what does a new fluoroquinolone offer?

Emilia Cercenado, Oscar Murillo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. ASP-COMPLEX: redefining antimicrobial stewardship to improve outcomes in high-risk patients with severe infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Emilia CercenadoServicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón, Madrid, Spain. ecercenado@gmail.com.ORCID 0000-0002-5279-3773
Oscar MurilloServicio de Enfermedades Infecciosas, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Spain.ORCID 0000-0001-5776-8422

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Delafloxacin is a novel anionic fluoroquinolone with a different chemical structure from currently marketed fluoroquinolones, which gives it distinct physicochemical characteristics, being active in both acidic and neutral environments. Delafloxacin is also unique in showing a dual-targeted equipotent inhibition of the essential bacterial enzymes DNA gyrase and topoisomerase IV, which may explain the very low frequencies of spontaneous mutations

Indexed as

Anti-Bacterial AgentsFluoroquinolonesDNA Topoisomerase IVDrug Resistance, BacterialGram-Negative BacteriaHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsdelafloxacinDNA Topoisomerase IVFluoroquinolonesAcute bacterial skin and skin structure infectionsCommunity-acquired bacterial pneumoniaDelafloxacinFluoroquinolonesMethicillin-resistantResistanceTopoisomerases

Identifiers

PMID41811471
PMCPMC13071785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.